JAK2 and myeloproliferative neoplasm: Because HSP90 is known to stabilize JAK2 and therefore is a potential therapeutic target in JAK2-dependent MPN associated with MF, inhibitors of HSP90 have also been explored (currently in clinical phase II)39, 40.